InsiderTrades

Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.

Accepted 2024-08-13 00:00:00 ET · period of report 2024-08-09 · accession 0001104659-24-089008 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-08-13 2024-08-09 RYTM Cramer Pamela J. CHRO S - Sale+OE $45.15 -49.0K 13.5K -78% -$2.21M
D 2024-08-13 2024-08-09 RYTM Cramer Pamela J. CHRO M - OptEx $19.02 +30.8K 62.5K +97% +$585.3K
D 2024-08-13 2024-08-09 RYTM Cramer Pamela J. CHRO M - OptEx $0.00 -30.8K 30.7K -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-08-09 S D 46,902 $45.13 15,604 D — — (F2) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $44.53 to $45.51. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
2 Common Common Stock 2024-08-09 S D 2,104 $45.62 13,500 D — — (F3) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $45.53 to $45.77. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
3 Common Common Stock 2024-08-09 M A 30,771 $19.02 62,506 D — —
4 Derivative Stock Options (Right to buy) 2024-08-09 M D 30,771 $0.00 30,736 D $19.02 · — to 2031-07-25 30,771 Common Stock (F4) The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.